Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Joseph Tuscano
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hairy Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Joseph Tuscano | P1/2 | B · 60 |
| Cyclophosphamide | Kite, A Gilead Company | P2 | BB |
| Cediranib | Alexey Danilov, MD | P1/2 | B |
| Fludarabine | Kite, A Gilead Company | P2 | B |
| Rituximab | Acerta Pharma BV | P1/2 | B |
| Obinutuzumab | Joseph Tuscano | P1/2 | B |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | B |
| Alemtuzumab | Fred Hutchinson Cancer Center | P2 | B |
| Etoposide | City of Hope Medical Center | P1/2 | B |
+33 more in the Hairy Cell Leukemia cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Hairy Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-hairy-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →